SGN LIV1A

Drug Profile

SGN LIV1A

Alternative Names: SGN-LIV1A

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 11 Oct 2017 Seattle Genetics signs a collaboration with Merck to evaluate SGN-LIV1A in combination with pembrolizumab
  • 11 Oct 2017 Seattle Genetics intends to evaluate SGN LIV1A as neoadjuvant treatment in the phase II I-SPY 2 trial for Breast Cancer
  • 11 Oct 2017 Seattle Genetics plans a phase Ib/II trial for Breast cancer in combination with pembrolizumab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top